智通财经网·2025-11-13 07:36Group 1 - The innovative drug sector shows strong performance, with notable stock price increases for companies such as 三生制药 (up 10.11%), 先声药业 (up 7.52%), and 百济神州 (up 7.34%) [1] - In Q3, the innovative drug sector's revenue grew by 1.98% year-on-year, while net profit attributable to shareholders increased by 7.25% year-on-year [1] - Despite adjustments since September, the overall trend for the innovative drug industry remains positive, supported by domestic policies and the Federal Reserve entering a rate-cutting cycle [1] Group 2 - The innovative drug sector continued to experience high revenue growth and profitability turnaround in Q3, indicating a long-term positive development trend [2] - The surge in business development (BD) transactions highlights the growth potential of the Chinese innovative drug industry [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with subsequent clinical data enhancing commercial certainty in global markets [2]